Dr. Chertkow is a practicing cognitive neurologist at the Baycrest Health Sciences  Centre, where he Is also Senior Scientist and Chair in Cognitive Neurology and Innovation at Baycrest’s Rotman Research Institute (now Baycrest Academy for Research and Education). Until 2018 he was a neurologist at McGill University and the Jewish General Hospital in Montreal. He is a Professor in the Dept. of Medicine (Neurology) at University of Toronto. At Baycrest he is also director of the new Bank Family Clinical Trials Research Unit and the recently opened Kimel Family Centre for Brain Health, a facility that works to prevent future dementia in people at risk. His major areas of research interest include early diagnosis of Alzheimer’s Disease, subtypes of dementia, and therapy of cognitive disorders in Alzheimer Disease and Frontotemporal dementia using neuromodulation approaches such as transcranial direct current stimulation. Dr. Chertkow is on Stanford University’s 2020 list of “Top 2% Cited Scientists”. Since 2014 Dr. Chertkow has been the Scientific Director for the Canadian Consortium on Neurodegeneration in Aging (CCNA), a national organization established by the Canadian government via CIHR and partners. CCNA brings together 400 leading Canadian dementia researchers to establish national teams and platforms to produce breakthroughs in the diagnosis and treatment of the dementing illnesses.